BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 16, 2024
Distillery Therapeutics

Inhibiting FST-IGF1R interaction for neuropathic pain

BioCentury | Nov 27, 2024
Discovery & Translation

Science Spotlight: Reducing immune rejection of stem cell-derived therapies

BioCentury’s roundup of translational innovation also includes a new target for arrhythmia and four papers with links to newcos
BioCentury | Oct 24, 2024
Product Development

Vaderis: A case study in navigating the orphan drug development maze

Company went from idea to clinical proof of concept for
BioCentury | Oct 21, 2024
Product Development

EGFR: A best-in-class strategy study

The target is one of industry’s most notable case studies in continued product differentiation and market growth 
BioCentury | Oct 7, 2024
Distillery Therapeutics

Inhibiting CCL7 for diabetic vascular disease

BioCentury | Aug 28, 2024
Product Development

Clinical Report: U.K. details plans to improve clinical trial infrastructure

Plus: Neurocrine’s schizophrenia therapy, Medicxi-backed Vaderis’ treatment for rare vascular disorder both look to advance; plus a miss for Leo’s Timber
BioCentury | Aug 1, 2024
Distillery Therapeutics

PIK3CG-degrading PROTAC for AML

BioCentury | Apr 10, 2024
Finance

How Goldman Sachs’ life sciences strategy aims to scale private biotechs

Recent investment in Alterome is one of six since 2022 intended to allow biotechs to reach milestones while staying private longer
BioCentury | Apr 5, 2024
Finance

Venture report: Nine-digit rounds for Obsidian, Alterome, Diagonal

Plus: Neurosterix launches with a potential competitor to the schizophrenia therapy developed by Karuna
BioCentury | Mar 26, 2024
Distillery Therapeutics

Inhibiting CHREBP for hepatocellular carcinoma

Items per page:
1 - 10 of 674
Help Center
Username
Request a Demo
Request Training
Ask a Question